Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease-atrial fibrillation ablation registry.
Tasuku YamamotoShinsuke MiyazakiYasuaki TanakaToshikazu KonoTadanori NakataAkira MizukamiDaisetsu AoyamaHirofumi AraiYuta TaomotoTomoki HorieRintaro HojoShiho KawamotoKento YabeKikou AkiyoshiNobutaka KatoYuichi OnoAtsushi SuzukiSeiji FukamizuYasutoshi NagataYasuteru YamauchiHiroshi TadaHitoshi HachiyaOsamu InabaAtsushi TakahashiMasahiko GoyaTetsuo SasanoPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023)
Despite most patients with ESKD undergoing AF ablation showing undertreatment with warfarin, major bleeding events are common while thromboembolic events are rare.